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Abstract
Early switch (ES) from intravenous (IV) to oral antibiotic therapy programmes is increasingly included as a component of hospital
antimicrobial stewardship initiatives that aim to optimize antimicrobial therapy while limiting toxicity and resistance. In terms of
prioritizing the most cost-effective stewardship interventions, ES has been seen as a ‘low-hanging fruit’, which refers to selecting the most
obtainable targets rather than confronting more complicated issues. Administration of highly bioavailable oral antibiotics should be
considered for nearly all non-critically ill patients and has been recommended as an effective and safe strategy for over two decades.
However, to accrue the most beneﬁt from ES, it should be combined with an early discharge (ED) plan, protocol, or care pathway.
Beneﬁts of this combined approach include improved patient comfort and mobility, reduced incidence of IV-line-related adverse effects,
reduced IV antimicrobial preparation time, decreased hospital stays, reduced antimicrobial purchasing and administration costs, decreased
patient deconditioning, and shortened recovery times. Results from published studies document decreases in healthcare resource use and
costs following implementation of ES programmes, which in most studies facilitate the opportunity for ED and ED programmes. Barriers
to the implementation of these programmes include clinician misconceptions, practical considerations, organizational factors, and a
striking lack of awareness of IV to oral switch guidance. These and other barriers will need to be addressed to maximize the
effectiveness of ES and ED programmes. As national antimicrobial stewardship programmes dictate the inclusion of ES and ED
programmes within healthcare facilities, programmes must be developed and success must be documented.
© 2015 Clinical Microbiology and Infection published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and
Infectious Diseases.
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Introduction
Intravenous (IV) antibiotics are typically prescribed for hospi-
talized patients with serious, often life-threatening, infections.
Results from a European point prevalence survey in acute-care
hospitals showed that the majority of patients with hospital-
acquired infections (70%) received IV antibiotic therapy,
although the rate ranged from a low of 50% in Scotland and
Wales (UK) and Sweden to a high of 90% in Greece and
Romania [1]. The duration of IV antibiotic therapy and hospital
stays also varied widely among European countries [2,3]. Re-
sults from a study evaluating the treatment of patients with
methicillin-resistant Staphylococcus aureus (MRSA) complicated
skin and soft-tissue infections (cSSTIs) showed that duration of
IV antibiotic therapy ranged from a low of 10.1 days in the UK
to a high of 18.6 days in Poland. Mean hospital length of stay
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ranged from a low of 15.2 days in the UK to a high of 25.0 days
in Portugal [2].
In many cases, patients remain hospitalized for the full
duration of IV antibiotic therapy. Although outpatient paren-
teral antibiotic therapy (OPAT) may be an option to reduce
length of stay for some patients, these programmes are much
more suited to areas where protracted parenteral antibiotic
treatment is required (e.g. in bone and joint infections) or the
availability of an effective, well-tolerated oral agent is limited.
Furthermore, these programmes are not uniformly available
throughout Europe [4], and evidence suggests that many pa-
tients who require home antibiotic therapy can be treated with
an oral agent at hospital discharge, particularly where the
course of antibiotic therapy is not prolonged [5]. Additionally,
the burden of OPAT for both the patient and medical profes-
sional can be high. Patients require a line in situ which increases
their risk of IV-line-related infections and, depending on OPAT
model (e.g. OPAT centre, hospital unit administration), trans-
portation to an outpatient infusion centre [6]. The impact of
emerging novel single-dose or two-dose infusion therapies on
the need for such OPAT infrastructure remains to be seen.
With the availability of potent, highly bioavailable oral anti-
biotics, there is an opportunity to promote switching from IV
to oral therapy earlier and potentially reduce length of stay as a
result. The availability of potent, highly bioavailable agents such
as oral quinolones, macrolides and cephalosporins over the last
two decades has transformed our ability to safely and effectively
manage patients with a range of infections [7]. However, con-
version from IV glycopeptides to oral therapy when treating
serious, resistant Gram-positive infections remained a challenge
until the introduction of linezolid in the early part of the last
decade [2].
In this narrative review we discuss from a hospital standpoint
the evidence to support the criteria for early switch (ES) and
early discharge (ED), the value of these clinical programmes
from a European perspective, and their implementation.
Early switch/early discharge criteria: deﬁned
Many hospitals are including ES and ED criteria as part of their
antimicrobial stewardship programmes. Antimicrobial stew-
ardship is deﬁned as
“coordinated interventions designed to improve and
measure the appropriate use of antimicrobial agents by
promoting the selection of the optimal antimicrobial drug
regimen including dosing, duration of therapy, and route
of administrations. The major objectives of antimicrobial
stewardship are to achieve best clinical outcomes related
to antimicrobial use while minimizing toxicity and other
adverse events, thereby limiting the selective pressure on
bacterial populations that drives the emergence of
antimicrobial-resistant strains. Antimicrobial stewardship
may also reduce excessive costs attributable to subopti-
mal antimicrobial use” [8].
Such stewardship programmes aim to promote the appro-
priate use of antibiotics through the use of standards and
guidelines, education, communication and audit [9]. Early switch
programmes focus on optimizing drug regimens and should be
used in conjunction with other stewardship programmes that
focus on minimizing antibiotic resistance.
Although criteria to use in ES programmes for patients with
community-acquired pneumonia are provided in national
guidelines [10,11], guidance for patients with other types of
infections is less clearly deﬁned. Numerous criteria were
evaluated in studies evaluating ES and ED programmes in pa-
tients with various types of infections including lower respira-
tory tract infections, urinary tract infections, SSTIs, intra-
abdominal infections (Table 1) [7,9,12–25]. Most programmes
assessed ES and ED eligibility 2–4 days following initiation of IV
antibiotic therapy. Typically at this time, culture and sensitivity
results are available and the decision to continue or change
treatment course can be made. Intravenous antibiotic therapy is
only recommended for patients who are severely ill, are unable
to tolerate oral antibiotic therapy, or need antimicrobial
coverage or tissue penetration not obtainable with oral anti-
biotic therapy [26].
Intravenous to oral switch programmes are described in
detail in the medical literature [9,12,14,16,17,19–21,23,24,27].
Although various criteria are included in these programmes, in
general, criteria can be divided into those that assess available
oral therapies, the patient’s clinical status, and the patient’s
ability to adequately absorb orally administered therapy. Ex-
amples of IV antibiotics that have an oral equivalent include
many penicillins, ﬂuoroquinolones and linezolid. Examples of
TABLE 1. Criteria used to determine patient eligibility for
intravenous to oral antimicrobial switch therapy
Criteria
Temperature <38°C or >36°C for 24–48 h; normalizing body temperature;
afebrile for at least 8–24 h [5,9,12,14,16–18,20,21,23,25]
No unexplained tachycardia, haemodynamic instability [7,9,14,16,21,23,25]
Clinical improvement, no clinical indication for intravenous therapy
[5,7,9,12,17–20,23,25]
Oral ﬂuids/food tolerated, no reason to believe oral absorption of antimicrobials
may be poor; may be by nasogastric/gastric feeding tube [5,7,9,12,14–20,22,
23,25]
Improving white blood cell count [5,9,12,14,16,17,20,23,25]
Improving C-reactive protein [5,9]
Suitable oral antimicrobial therapy [9,12,23,24,33]
No surgery scheduled within next 24–36 h [16,25]
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criteria used to assess a patient’s clinical status include tem-
perature, white blood cell count and C-reactive protein as well
as general overall clinical improvement. Examples of criteria
used to assess a patient’s ability to tolerate oral therapy include
the ability to tolerate oral food or ﬂuids and no reason to
believe that oral therapy will be poorly absorbed.
We evaluated the likelihood and timing of meeting standard
ES and ED criteria in a chart review study that captured data on
1502 randomly selected patients with MRSA cSSTI in 12 Eu-
ropean countries [2,25]. Data were obtained from hospital
records of patients aged 18 years or older who were hospi-
talized with a documented MRSA cSSTI between 1 July 2010
and 30 June 2011 and discharged alive by 31 July 2011. Study
investigators determined whether patients met each ES and ED
criterion before discontinuation of IV therapy (either switching
from IV to oral antibiotics or discharge) and discharge,
respectively, and the number of days from cSSTI diagnosis to
meeting criteria. Results of the evaluation are shown in Tables 2
and 3. Less than half of patients were identiﬁed as having a
normalizing white blood cell count or stable clinical infection
before discontinuation of IV therapy, with a median of 7 days
from initiation of IV therapy to meeting these criteria. Patients
were more likely to be afebrile, without tachycardia or hypo-
tension, and to tolerate oral ﬂuids/diet before discontinuation
of IV therapy, and met these criteria earlier. With respect to
early discharge criteria, over two-thirds of patients had stable
clinical infections and improving white blood cell counts before
discharge, but the median time to meeting these criteria (9
days) was longer than any other. Patients had other reasons to
be hospitalized for a median of 8 days after cSSTI diagnosis, and
less than half of patients met this criterion before discharge.
Hence, it appears that the physician’s assessment of clinical
improvement and normalizing white blood cell counts would be
important determinants of length of IV therapy and hospital stay
TABLE 2. Patients with methicillin-resistant Staphylococcus aureus complicated skin and soft-tissue infections (n = 1502) meeting
early switch criteria before intravenous discontinuation
Early switch criteriaa
Patients
Days from start of IV antibiotic
therapy to meeting criteria
n % Median (Range)
Stable clinical infection 663 44.1 7.0 (0–98)
Afebrile/temperature <38°C for 24 h 839 55.9 5.0 (0–98)
White cell count normalizing (>4 × 109 but <12 × 109 cells/L) 734 48.9 7.0 (0–98)
No unexplained tachycardia 789 52.5 4.0 (0–98)
Systolic blood pressure 100 mmHg 815 54.3 3.0 (0–98)
Tolerates oral ﬂuids/diet and able to take oral medication with no gastrointestinal
absorption problems
804 53.5 3.0 (0–98)
Available bacteriology for MRSA cSSTIs sensitive to oral antibiotic treatment 970 64.6 2.0 (0–43)
Available bacteriology for MRSA cSSTIs sensitive to OPAT antibiotic treatment 1043 69.4 2.0 (0–43)
No surgery scheduled for next 36 h 530 35.3 4.0 (0–98)
No requirement for IV line except IV antibiotic therapy 465 31.0 4.0 (0–45)
cSSTI, complicated skin and soft-tissue infection; IV, intravenous; MRSA, methicillin-resistant Staphylococcus aureus; OPAT, outpatient parenteral antimicrobial therapy.
aCriteria must be met before actual MRSA active IV antibiotic discontinuation.
TABLE 3. Patients with methicillin-resistant Staphylococcus aureus complicated skin and soft-tissue infections (n [ 1502) meeting
early discharge criteria before actual discharge
Early discharge criteria
Patients
Days from diagnosis
to meeting criteria
n % Median (range)
No other reason to stay in the hospital except infection management 716 47.7 8.0 (0–122)
Stable mental status 796 50.3 2.0 (0–122)
Stable comorbid illness 755 50.3 4.0 (0–269)
Stable social situation 709 47.2 1.0 (0–122)
Stable clinical infection 1004 66.8 9.0 (0–138)
Afebrile/temperature <38°C for 24 h 1091 72.6 6.0 (0–138)
White cell count normalizing (>4 × 109 but <12 × 109 cells/L) 1032 68.7 8.0 (0–138)
No unexplained tachycardia 1007 67.0 5.0 (0–138)
Systolic blood pressure 100 mmHg 1028 68.4 4.0 (0–138)
Tolerates oral ﬂuids/diet and able to take oral meds with no gastrointestinal absorption problems 1043 69.4 4.0 (0–138)
Available bacteriology for MRSA cSSTIs sensitive to oral antibiotic treatment 1101 73.3 2.0 (0–94)
Available bacteriology for MRSA cSSTIs sensitive to OPAT antibiotic treatment 1157 77.0 2.0 (0–94)
No surgery scheduled for next 36 h 658 43.8 5.0 (0–94)
No requirement for IV line except IV antibiotic therapy 626 41.7 6.0 (0–77)
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if these criteria were applied prospectively. This ﬁnding is
consistent with other studies, which suggest that the most
common reason for not switching patients from IV to oral
therapy is lack of clinical improvement [9,19].
Beneﬁts of ES and ED programmes
In terms of prioritizing the most cost-effective stewardship in-
terventions, ES has been seen as a ‘low-hanging fruit’, which in
reference to stewardship, refers to selecting the most obtainable
targets rather than confronting more complicated management
issues [28]. These strategies require fewer resources and less
effort than other stewardship activities; however, they are appli-
cable to a variety of healthcare settings, including limited-resource
hospitals, and have demonstrated signiﬁcant ﬁnancial savings.
The goals of an ES and ED programme are to decrease both
the duration of IV antimicrobial therapy and the length of
hospitalization while maintaining equivalent effectiveness. Ben-
eﬁts of ES programmes that facilitate switching from IV to oral
antimicrobial therapy include the following: improved patient
comfort and mobility [5,17], reduced incidence of IV-line
related adverse effects such as catheter-related bacteraemia
and phlebitis [5,16,29], reduced nursing or pharmacy time spent
preparing IV antimicrobials [5,17,30], decreased hospital length
of stay [2,5,17,18,20,24,29,31] and reduced antimicrobial pur-
chasing and administration costs [17,24]. Additionally, when
clinical outcomes are equivalent, patients prefer oral therapy to
IV therapy [32]. Beneﬁts of ES followed by ED programmes
include a lower risk of line-related infections [29], less patient
deconditioning [5,23], and a shorter recovery time [23].
The beneﬁts of ES programmes are well recognized in patients
with community-acquired pneumonia. Guidelines for IV to oral
switch therapy in patients with community-acquired pneumonia
are included in national guidelines published by the British
Thoracic Society [10] and the Infectious Diseases Society of
America/American Thoracic Society [11]; the latter additionally
includes criteria for ED. The actual or potential beneﬁts of ES and
ED programmes were demonstrated in numerous studies
enrolling patients with various types of infections including those
caused by bacteria and fungi [7,9,12–25,29,33]. Indeed, in chil-
drenwith pyelonephritis early IV to oral switchwas deemed non-
inferior to IV therapy only, thereby providing further evidence to
support this intervention [34].
Impact on healthcare resource use
Results from a 2003 Canadian study suggested a potential
decrease in both IV treatment and hospitalization length for
patients hospitalized with an MRSA SSTI and treated with van-
comycin [15]. Study results showed the potential for a saving of
14.5 IV-therapy-days for patients who met ES criteria, had they
been switched to a suitable oral agent. The most frequently cited
reason for not switching to oral therapy was the lack of an
effective oral treatment as the study was conducted before the
availability of linezolid. Twelve years later, the signiﬁcant po-
tential for reduction in length of IV treatment and hospitalization
has been identiﬁed for patients hospitalized with an MRSA cSSTI
in Europe [25]. In this real-world study, 504 of the 1502 enrolled
patients (33.6%) met ES and ED criteria. Administration of an
oral therapy active against MRSA had the potential to decrease
the IV therapy duration by 6.0 ± 5.5 days and hospital length of
stay by 6.2 ± 8.2 days. Another study from the UK including 211
patients within the same disease context found that 29% of pa-
tients receiving at least 5 days of IV glycopeptide therapy were
eligible for ES and ED, saving 649 inpatient days over a 6-month
period. An additional 247 IV antibiotic therapy days were saved
by patients meeting ES but not ED criteria [16].
Results from a study conducted in Norway, across a range of
infections, showed a signiﬁcant decrease in IV therapy duration
and hospital length of stay following implementation of ES
guidelines [24]. Unnecessary IV therapy decreased in duration
from 3.4 to 1.4 days and hospital stay from 7.0 to 6.3 days
following implementation of ES guidelines. Importantly, no dif-
ference in mortality, need to restart IV therapy, or readmission
rate was found.
The impact of a three-step critical pathway among patients
hospitalized with community-acquired pneumonia was evalu-
ated in a randomized trial conducted in two tertiary care
hospitals in Spain. Recommendations for early mobilization of
patients, use of objective criteria for switching from IV to oral
antibiotics, and speciﬁc criteria for hospital discharge were
implemented using a printed checklist placed in the chart of
patients randomized to the critical pathway arm, with the
control group receiving usual care. Use of the critical pathway
was associated with a 2-day reduction in median length of IV
therapy and a 2-day reduction in length of stay, with no detri-
ment to safety measured by adverse events, hospital read-
mission and mortality [29].
Impact on costs
Costs appear to be decreased in patients switched from IV to
oral therapy. In a UK-based study conducted in medical and
surgical wards across ﬁve UK hospital trusts, it was estimated
that an ES and ED programme could save £363 per patient in
total costs, of which £32 was attributable to switching from IV to
oral antibiotic therapy alone [31]. Additional savings from
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shorter hospital stays was also reported. Application of ES and
and ED criteria retrospectively to patients with MRSA cSSTIs in a
pan-European chart review study suggested potential savings of
more than V2000 in bed-day costs per ED eligible patient [25].
Cost savings may be even greater if indirect costs for drug
administration are included in calculations. In a Dutch study, the
average time required for drug administration by volumetric
pump, syringe pump, ‘unaided’ infusion bag, and direct IV in-
jection represented between 11% and 53% of the total antibi-
otic therapy daily costs [30]. These indirect costs ranged from
13% to 113% of antibiotic acquisition costs. The cost to insert
an IV catheter was not included in this cost calculation, but was
estimated at V9.17. In a separate study of 694 patients with
various infection types, application of an ES checklist was esti-
mated to reduce nurse workload by 350 hours per year [19].
Implementation
Country-speciﬁc programmes
Many countries are starting to include IV to oral switch therapy
initiatives as a component of their national antimicrobial
stewardship programmes. However, antimicrobial stewardship
programmes are not consistently used among European na-
tions. Evidence from the European Society of Clinical Micro-
biology and Infectious Disease (ESCMID) Study Group for
Antibiotic Policies (ESGAP) global survey of antimicrobial
stewardship shows that 81% of European countries and 73% of
European hospitals have antimicrobial stewardship standards;
66% of hospitals have antimicrobial stewardship programmes in
place [35]. Various strategies are used by these stewardship
programmes, with approximately 82% of European hospitals
with stewardship programmes participating in this survey hav-
ing an IV to oral switch programme [35].
The UK, Belgium, Austria and Germany all have antimicro-
bial stewardship initiatives that incorporate IV to oral switch
therapy programmes. For example, the Advisory Committee
on Antimicrobial Resistance and Healthcare Associated In-
fections in England initiated the ‘Start Smart—then Focus’
programme. This national antimicrobial stewardship pro-
gramme contains an IV to oral switch component (Fig. 1) [26].
This initiative focuses on a review of antimicrobial therapy 48 h
after treatment initiation. The best practice standard for IV to
oral switch therapy is that IV antibiotics be switched to oral
therapy within 24 h of the patient meeting local switch criteria.
Recommendations are to audit IV to oral switch programmes
annually or monitor the consumption of IV compared with oral
antimicrobial therapy.
The Scottish Antimicrobial Prescribing Group (SAPG) is
responsible for implementation of the Scottish Management of
Antimicrobial Resistance Action Plan (ScotMARAP) [36]. The
ScotMARAP includes IV to oral switch guidance for patients
receiving empirical antimicrobial therapy.
Sequential IV to oral therapy is also a component of the
majority of antimicrobial stewardship programmes supported
by the Belgian Antibiotic Policy Coordination Committee
(BAPCOC) [37]. The BAPCOC supports the development of
antibiotic management teams through policy guidance and
federal funding for antibiotic managers. Sequential IV to oral
therapy guidelines are used by approximately 79% of the anti-
biotic management teams.
Intravenous to oral switch programmes are core activities of
antimicrobial stewardship programmes in Austria and Germany
[38]. The quality indicator states that hospitals should have written
recommendations for parenteral-to-oral switch antimicrobial
therapy available and that they are updated every 2 years. Similarly, a
quality indicator was developed and proposed for assessing the
appropriate IV to oral switch of bioavailable antibiotics. This is
believed to be a feasible and clinically relevant approach to
measuring the implementationof the interventions andmayprovide
the quality improvement leverage within healthcare systems [14].
Lastly, to ensure greater consistency of stewardship indicators,
the Transatlantic Taskforce on Antimicrobial Resistance [TAT-
FAR] group has developed through a formal Delphi process
structural and process indicators for stewardship; the availability
of IV to oral switch guidance is a key supplementary indicator (D.
Nathwani, personal communication). Such international guidance
again supports the value of this stewardship strategy.
Hospital-speciﬁc programmes
Numerous examples of hospital-speciﬁc ES and ED programmes
are available in the published medical literature [7,9,12–24].
Most programmes evaluate a patient’s ability to take oral therapy
2–3 days after initiation of IV therapy (Fig. 2). Although different
approaches to programme implementation are used, most of
these programmes through the use of policies, treatment
guidelines, surveillance data, educational resources, targeted
intervention and audit aim to reduce the number of IV inpatient
antibiotic days. Successful programmes typically include imme-
diate feedback, which is directed to the physician-in-charge and
contain patient-speciﬁc, clear, unambiguous advice [7].
Barriers to implementation
Country level
Several barriers to implementation of ES and ED programmes
at a national level are described in the medical literature. The
inclusion of an IV to oral switch programme in a national
antimicrobial stewardship initiative does not guarantee the
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acceptance or success of the programme at a hospital level [39].
Evidence from England suggests that acceptance of nationally or
centrally developed programmes is slow. Prescribing appears to
be inﬂuenced by the cultural beliefs of the patient and the
prescriber, patient demand, socio-economic factors, and clinical
autonomy, not national guidelines [40,41]. To improve uptake
of national guidelines, recommendations are to develop
consensus documents through collaboration of key stake-
holders at the national level and disseminate these recom-
mendations at a local level through the identiﬁcation and
professional development of local leaders [42].
Unit/hospital level
Barriers to ES and ED at a unit/hospital level include stafﬁng
time constraints, stafﬁng changes and prescribing etiquette
[43,44]. Reassessment of antimicrobial therapy after 48–72 h of
treatment is often neglected because of time constraints and
changes in stafﬁng [19]. Information on why the antimicrobial
was started and the goal of therapy may not be communicated
among clinical teams resulting in the unnecessary continuation
of antibiotic therapy including unnecessary IV therapy. In many
institutions, prescribing etiquette, or the reluctance of junior
medical staff members to change the prescribing habits of more
senior staff members, determines or inﬂuences treatment
patterns [43]. Changes to antibiotic regimens are often made by
more senior medical staff, who typically review patient medical
charts less frequently than junior staff members.
Prescriber level
Prescribers are often hesitant to modify an apparently efﬁcacious
empirical therapy, especially if there is no direct oral equivalent
for the IV formulation [45]. To overcome this barrier, precise
recommendations should be offered when requesting a change
from an IV antibiotic with no direct oral equivalent formulation.
Potentially, ES and ED programmes may beneﬁt by administra-
tion of IV antibiotics with highly bioavailable oral formulations, by
offering precise guidelines regarding which oral antibiotics can be
substituted for IV antibiotics or be used to treat speciﬁc condi-
tions, or by providing an infectious disease consult [46]. Other
prescriber-speciﬁc barriers identiﬁed include time constraints,
rapid rotation of physicians in charge of patients, and the belief
that IV therapy is superior to oral therapy [22,44].
FIG. 1. Antimicrobial Stewardship in Secondary Care, Antimicrobial Stewardship Algorithm [26].
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Conclusions
The beneﬁts of ES and ED programmes to patients and pro-
viders are many. Patient beneﬁts include increased comfort
and mobility, decreased risk of IV-line related adverse effects,
and improved recovery times. Provider beneﬁts include
decreased IV preparation time, potential for reduced hospital
length of stays, and decreased antimicrobial purchasing and
administration costs. Therefore, ES and ED programmes have
the potential to offer improved quality of care at reduced
total cost, thereby providing a powerful and persuasive
argument for adoption and implementation [47].
Antimicrobial stewardship programmes should incorporate
not only ES and ED initiatives that focus on optimizing drug
regimens but additional initiatives that focus on minimizing
drug resistance.
Recommendations for implementing ES and ED programmes
in hospitals are shown in Table 4. It is important for hospitals to
engage key stakeholders early in the planning process, in order
to identify and respond to potential barriers to adherence.
Multi-pronged approaches that provide clear and explicit
feedback are the most likely to succeed in altering prescribing
behaviour. Measuring and feeding back the beneﬁts of these
programmes will also be instrumental in generating continued
buy-in from practitioners and administrators [48].
FIG. 2. Example of intravenous to oral
switch policy [9]. Reproduced from McCal-
lum et al. [9] with permission from the
authors.
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